Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

NCT03622580
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 30, 2026, 9:22 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Visual Function Study

NCT00001346
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block

NCT04559425
View directory record Official record
Conditions
Heart Block Complete, Heart Block Second Degree
Interventions
Dexamethasone, No Dexamethasone
Drug · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
350 participants
Timeline
2020 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Nebulized Albuterol on Donor Oxygenation

NCT00310401
View directory record Official record
Conditions
Brain Death, Organ Donor, Pulmonary Edema
Interventions
Albuterol, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
14 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 30, 2026, 9:22 PM EDT
Withdrawn Early Phase 1 Interventional

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation

NCT03330704
View directory record Official record
Conditions
Cerebral Edema, Saline Solution, Hypertonic
Interventions
3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 30, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

NCT05505500
View directory record Official record
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional Results available

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions
Fingolimod, Placebo, Open-label Fingolimod
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 30, 2026, 9:22 PM EDT
Active, not recruiting Phase 3 Interventional

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 9:22 PM EDT
Not yet recruiting Phase 1 Interventional

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma

NCT07791264
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
Interventions
Biospecimen Collection, Computed Tomography, Dexamethasone, Invasive Procedure, Magnetic Resonance Imaging, RAGE Antagonist FPS-ZM1, Resection
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

NCT00226655
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF [XERECEPT (corticorelin acetate injection)]
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Newport Beach, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 30, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006916
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bleomycin, Ommaya reservoir, radiation therapy
Biological · Device · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
13
States / cities
Phoenix, Arizona • Lexington, Kentucky • Omaha, Nebraska + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 30, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images

NCT07568704
View directory record Official record
Conditions
Retina Pathology
Interventions
Dream OCT
Device
Lead sponsor
Intalight, Inc
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 30, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

NCT07060001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions
5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline
Diagnostic Test · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 9:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

NCT01918371
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Anti-VEGF
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 30, 2026, 9:22 PM EDT
Completed No phase listed Observational

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 30, 2026, 9:22 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluation of Tonabersat for DME

NCT05727891
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Tonabersat, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Huntington Beach, California • Loma Linda, California • Oakland, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

NCT04894110
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
Interventions
EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
Biological
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 4 Interventional

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

NCT00115726
View directory record Official record
Conditions
Hypertension, Hypotension, Edema, Congestive Heart Failure
Interventions
furosemide, placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2008 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Results available

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen® pegaptanib sodium
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 30, 2026, 9:22 PM EDT
Not listed Phase 4 Interventional

Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME

NCT04038125
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Interventions
Ozurdex Drug Implant Product
Drug
Lead sponsor
Retina Macula Specialists of Miami, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
North Miami Beach, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 30, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Glyburide for Injection
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 30, 2026, 9:22 PM EDT